Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551303 | 0.86 | HSD11B1 (0.51) | TDP1TSHRKMT2AMEN1KDM4E | |
| SCHEMBL13198360 | 0.86 | GSTO1 (0.47) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL3120142 | 0.86 | TSPO (0.47) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL10773942 | 0.84 | KMT2A (0.47) | TDP1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3119603 | 0.83 | NPC1 (0.49) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL28821061 | 0.83 | RAB9A (0.57) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL7405546 | 0.80 | NPC1 (0.48) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL28394274 | 0.79 | AGER (0.55) | TDP1NPC1RAB9AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL11685888 | 0.78 | NPC1 (0.47) | TDP1TSHRNPC1RAB9ACA12 | |
| SCHEMBL2963704 | 0.78 | GAA (0.49) | TDP1TSHRCA12CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4327568-A | — | — | None | — | — | JP | disclosed |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | HUVAL CHAD (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100135950-A1 | Iron(II)-Containing Treatments for Hyperphosphatemia | GENZYME CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2043627-A2 | IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | Genzyme Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005217-A2 | IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | GENZYME CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-0743299-B1 | Process for the preparation of 2-fluorocyclopropylamine sulfonic acid salts | BAYER AG (DE) | 1999-09-15 | — | — | EP | disclosed |
| US-5646329-A | Cyclopropylamine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-08 | — | — | US | disclosed |
| EP-0711750-A1 | Process for preparing 2-fluoro-cyclopropylamine as well as novel cyclopropylamine derivatives | BAYER AG (DE) | 1996-05-15 | — | — | EP | disclosed |
| JP-H04327568-A | FLUOROCYCLOPROPYL CARBAMATE DERIVATIVE AND PRODUCTION THEREOF | DAI ICHI SEIYAKU CO LTD | 1992-11-17 | — | — | JP | disclosed |
| EP-0132679-A2 | Copolymers containing primary amino groups, their manufacture and their use as technological auxiliary substances | BAYER AG (DE) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135950-A1 | Iron(II)-Containing Treatments for Hyperphosphatemia | FECH, SLC20A2, SDHB | TDP1 3360/4885TSHR 1574/4885NPC1 1553/4885 |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | SLC20A2, PFKFB2, SLC46A1 | TDP1 3726/4885TSHR 1766/4885NPC1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.